Simvastatin (Zocor, Flolipid, generic formulations available)
Other Medications · Approved since 1991
Description
Simvastatin is an HMG-CoA reductase inhibitor (statin) traditionally used to lower cholesterol that is being repurposed for colorectal cancer treatment based on its potential anti-tumor properties. In CRC, simvastatin is combined with standard chemotherapy regimens like FOLFIRI or XELOX plus bevacizumab to potentially enhance treatment efficacy in metastatic disease. The drug's cholesterol-lowering mechanism may disrupt cancer cell membrane function and cellular signaling pathways that promote tumor growth and metastasis.
Mechanism of Action
Simvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, which reduces cellular cholesterol production and affects membrane composition. In cancer cells, this mechanism may disrupt lipid raft formation and interfere with oncogenic signaling pathways, potentially leading to reduced cell proliferation, increased apoptosis, and decreased metastatic potential.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Zocor, Flolipid, generic formulations available |
| Category | Other Medications |
 Status | Off-label |
| Administration | Oral |
| Year Approved | 1991 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.